Rebinding done by Spiralverse™
1 1

The LDN Book, Volume Two: The Latest Research on How Low Dose Naltrexone Could Revolutionize Treatment for PTSD, Pain, IBD, Lyme Disease, Dermatologic Conditions, and More Spiral-Bound |

Linda Elsegood

$40.58 - Free Shipping

A comprehensive examination of Low Dose Naltrexone—a little-known drug with big potential

"[LDN] raises hopes of reversing memory loss in old age."—the Guardian

A drug that is simultaneously affordable, devoid of severe side effects, and applicable to a wide range of diseases is not often found in the modern pharmaceutical landscape. But as medical professionals and researchers alike continue to discover, Low Dose Naltrexone (LDN) boasts this remarkable combination.

LDN, originally prescribed in higher doses as a treatment for opioid addiction, works by blocking opioid receptors, thereby stimulating the production of endorphins, mitigating the inflammatory process, and stabilizing the immune response. Prescribed off-label and administered in small daily doses, this generic drug has proven useful in treating many different ailments.

Expanding on the information presented in The LDN Book, Volume 1, which showcased LDN’s efficacy in treating conditions such as lupus, thyroiditis, autism spectrum disorder, and chronic fatigue, Volume 2 highlights the latest clinical trials, case studies, and research with explanations from a dozen medical professionals on how they are using LDN to help patients suffering from:

  • Chronic pain
  • Parkinson’s disease
  • Dermatologic conditions
  • Traumatic brain injury 
  • Lyme disease and more

The LDN Book, Volume 2 is both a resource for practitioners, pharmacists, and patients, and a renewed call for further research on the healing potential of this generic drug.

Publisher: Chelsea Green Publishing
Original Binding: Paperback
Pages: 288 pages
ISBN-10: 1603589902
Item Weight: 0.9 lbs
Dimensions: 6.0 x 0.8 x 9.0 inches

“Since the first volume of The LDN Book was released, I have had the distinct privilege of learning from and collaborating with the best clinicians and researchers in the field of integrative medicine. Through these collaborations, we continue to build upon the already vast applications of this low-dose but high-power medication. I am thrilled to see so many trusted colleagues, who have also become friends, contribute to this important body of work. Thank you, again, Linda Elsegood, for bringing together a tribe of like-minded people who continue to find solutions to challenging medical issues with this simple and inexpensive intervention.”—Dr. Nasha Winters, ND, FABNO, author of The Metabolic Approach to Cancer

Linda Elsegood is the founder of the LDN Research Trust, which was set up in the UK as a Registered Charity in 2004, and is the editor of The LDN Book. Diagnosed with MS in August of 2000, she started LDN therapy in December of 2003, and now has a better quality of life and hope for the future. Through the Trust, she has connected thousands of patients, doctors, and pharmacists around the world with information, articles, and patient stories about LDN.